المحتويات
Update: September 2022
Forms and strenghts
- 250 mg and 500 mg tablets
-
100 mg dispersible tablet, to be dispersed in 10 ml water
Dosage
- Child under 30 kg: 15 to 20 mg/kg once daily
- Child 30 kg and over and adult: 750 to 1000 mg once daily
- Maximum dose: 1500 mg daily
- Renal insufficiency: 750 to 1000 mg 3 times a week
|
Weight |
Daily dose |
500 mg |
250 mg |
100 mg dispersible tablet |
|---|---|---|---|---|
|
5 |
75-100 |
− |
− |
1 tab |
|
6 |
90-120 |
− |
− |
1 tab |
|
7 |
105-140 |
− |
− |
1½ tab |
|
8 |
120-160 |
− |
− |
1½ tab |
|
9 |
135-180 |
− |
− |
1½ tab |
|
10 |
150-200 |
− |
− |
2 tab |
|
11 |
165-220 |
− |
− | 2 tab |
|
12 |
180-240 |
− |
− | 2 tab |
|
13 |
195-260 |
− |
− | 2 tab |
|
14 |
210-280 |
− |
− | 2 tab |
|
15 |
225-300 |
− |
− | 2 tab |
|
16 |
240-320 |
− |
− | 3 tab |
|
17 |
255-340 |
− |
− | 3 tab |
|
18 |
270-360 |
− |
− | 3 tab |
|
19 |
285-380 |
− |
− | 3 tab |
|
20 |
300-400 |
− |
3 tab | |
|
21 |
315-420 |
− |
− | 4 tab |
|
22 |
330-440 |
− |
− | 4 tab |
|
23 |
345-460 |
− |
− | 4 tab |
|
24 |
360-480 |
− |
− | 4 tab |
|
25 |
375-500 |
− |
2 tab |
− |
|
26 |
390-520 |
− |
2 tab | − |
|
27 |
405-540 |
− |
2 tab | − |
|
28 |
420-560 |
− |
2 tab | − |
|
29 |
435-580 |
− |
2 tab | − |
|
|
||||
|
30-35 |
750 |
− |
3 tab |
− |
|
36-45 |
750 |
− |
3 tab |
− |
|
46-55 |
1000 |
2 tab |
− |
− |
|
56-70 |
1000 |
2 tab |
− |
− |
|
> 70 |
1000 |
2 tab |
− |
− |
Contra-indications, adverse effects, precautions
- Do not administer to patients with hypersensitivity reaction or tendon damage during a previous treatment with a fluoroquinolone.
- Administer with caution to patients:
- over 60 years or on corticosteroid treatment (increased risk of tendon damage);
- with diabetes or history of psychiatric disorders or seizures.
- May cause:
- tendinitis, tendon rupture, mild QT prolongation;
- gastrointestinal disturbances (abdominal or epigastric pain, diarrhoea);
- nervous system and psychiatric disorders (headache, seizures, psychosis, etc.);
- photosensitivity;
- hypersensitvity reactions, hypo/hyperglycaemia;
- rarely: crystalluria, peripheral neuropathy, ototoxicity.
- For the management of adverse effects, see Appendix 17.
- Avoid or use with caution and under close monitoring in patients taking other QT prolonging drugs (Appendix 19) or warfarin.
- Do not administer simultaneously with antacids containing magnesium/aluminium, calcium, iron and zinc salts (administer 2 hours apart).
Pregnancy: use if the benefits outweigh the risks (safety not established).
Breastfeeding: avoid breastfeeding during treatment (no absolute contra-indication).
Monitoring
- Symptomatic monitoring.
Patient instructions
- Take 2 hours apart from milk-based product, antacids, calcium, iron and zinc salts.
- 100 mg tablets should be dispersed in 10 ml water.
- Maintain a good fluid intake.
- Protect your skin from sun.
Storage
–
– Below 25 °C